^
    1year
    Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=11, Completed, TransThera Sciences (Nanjing), Inc. | Recruiting --> Completed | N=20 --> 11 | Trial completion date: Dec 2022 --> Oct 2023 | Trial primary completion date: Aug 2022 --> Oct 2023
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    TT-00434
    1year
    First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors (ESMO Asia 2023)
    The preliminary antitumor activity was observed in pt with FGFR2 altered cholangiocarcinoma. Further evaluation of the efficacy and safety of TT-00434 in solid tumors with FGFR1-3 alterations is encouraged.
    Clinical • P1 data • Metastases
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR (Fibroblast Growth Factor Receptor)
    |
    FGFR2 fusion
    |
    TT-00434